Edward Keystone

Edward Keystone

UNVERIFIED PROFILE

Are you Edward Keystone?   Register this Author

Register author
Edward Keystone

Edward Keystone

Publications by authors named "Edward Keystone"

Are you Edward Keystone?   Register this Author

100Publications

2896Reads

42Profile Views

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.

Ann Rheum Dis 2019 Jul 30;78(7):890-898. Epub 2019 Apr 30.

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214529DOI Listing
July 2019

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

J Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171469DOI Listing
January 2019

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Arthritis Care Res (Hoboken) 2018 Aug 13;70(8):1185-1191. Epub 2018 Jul 13.

Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23457DOI Listing
August 2018

The Dorsal 4-finger Technique: A Novel Method to Examine Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis.

J Rheumatol 2018 Mar 15;45(3):329-334. Epub 2018 Jan 15.

From the Division of Rheumatology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Division of Rheumatology, Department of Medicine, and Division of Musculoskeletal Imaging, Department of Medical Imaging, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.161507DOI Listing
March 2018

Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29].

Clin Immunol 2018 02 7;187:137-138. Epub 2017 Dec 7.

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Pathology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2017.11.012DOI Listing
February 2018

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

J Rheumatol 2018 01 15;45(1):14-21. Epub 2017 Aug 15.

Kennedy Institute of Rheumatology and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.161161DOI Listing
January 2018

Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

Ann Intern Med 2017 Jul 30;167(1):8-16. Epub 2017 May 30.

From University of British Columbia and St Paul's Hospital, Vancouver, British Columbia, Canada; Palo Alto Veterans Affairs (VA) Health Care System, Palo Alto, and Stanford University School of Medicine, Stanford, California; VA Nebraska-Western Iowa Health Care Center and University of Nebraska Medical Center, Omaha, Nebraska; Boston University School of Medicine, Boston, Massachusetts; and University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/M16-0713DOI Listing
July 2017

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

N Engl J Med 2017 02;376(7):652-662

From the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences and the Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom (P.C.T.); the Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto (E.C.K.); Leiden University Medical Center, Leiden, the Netherlands (D.H.); Brigham and Women's Hospital, Boston (M.E.W.); Instituto Reumatológico Strusberg, Córdoba, Argentina (L.C.M.); Centro de Investigacion Clinica Especializada, Mexico City (J.R.G.); Ryazan Regional Clinical Cardiology Dispensary, Ryazan, Russia (S.Y.); Eli Lilly, Indianapolis (T.I., S. Beattie, V.A., C.G., T.R., D.S., W.L.M., S. de Bono); and AstraZeneca K.K., Osaka (K.E.), and the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu (Y.T.) - both in Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1608345DOI Listing
February 2017

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.

J Rheumatol 2016 12 1;43(12):2120-2130. Epub 2016 Nov 1.

From the Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center, and University of Massachusetts Medical School, Worcester, Massachusetts; Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, Texas; Janssen Research and Development LLC, Spring House; University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada; Rheumatology, Rheumazentrum Ruhrgebeit, Herne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160420DOI Listing
December 2016

Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome.

Clin Immunol 2016 07 22;168:25-29. Epub 2016 Apr 22.

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Pathology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2016.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940221PMC
July 2016

High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.

Medicine (Baltimore) 2016 Jul;95(28):e3968

aDepartment of Rheumatology and Immunology, Peking University People's Hospital bDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing cDepartment of Clinical Immunology, Fourth Military Medical University Xijing Hospital, Xi'an dDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing eDepartment of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing fDepartment of Rheumatology and Immunology, Fudan University Huashan Hospital, Shanghai gDepartment of Rheumatology and Immunology, Shandong University Qilu Hospital, Jinan hDepartment of Rheumatology and Immunology, Sichuan University West China Hospital, Chengdu iDepartment of Rheumatology and Immunology, Third Military Medical University Southwest Hospital, Chongqing, China jThe Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, University of Toronto, Toronto, Canada kInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000003968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956780PMC
July 2016

The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.

Ann Rheum Dis 2016 Jun 15;75(6):1003-8. Epub 2015 May 15.

Mount Sinai Hospital, Toronto, Ontario, Canada Hospital for Special Surgery, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2014-206504DOI Listing
June 2016

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.

RMD Open 2016 26;2(1):e000225. Epub 2016 May 26.

Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Clinical Trials Unit, McGill University, Montreal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2015-000225DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885442PMC
June 2016

Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

PLoS One 2015 24;10(8):e0135327. Epub 2015 Aug 24.

Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135327PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547697PMC
May 2016

X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Arthritis Rheumatol 2016 05;68(5):1290-1300

College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.39560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019501PMC
May 2016

Fibrocyte and T cell interactions promote disease pathogenesis in rheumatoid arthritis.

J Autoimmun 2016 May 3;69:38-50. Epub 2016 Mar 3.

Toronto General Research Institute, University Health Network, Toronto, Canada; Department of Immunology, University of Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2016.02.008DOI Listing
May 2016

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.

Arthritis Care Res (Hoboken) 2016 Mar;68(3):299-307

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/acr.22676
Publisher Site
http://dx.doi.org/10.1002/acr.22676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067694PMC
March 2016

Subcutaneous abatacept in rheumatoid arthritis: current update.

Expert Opin Biol Ther 2015 ;15(8):1221-30

Mount Sinai Hospital , Toronto, Ontario , Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.1065248DOI Listing
February 2016

Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.

J Rheumatol 2016 Feb 15;43(2):298-306. Epub 2015 Dec 15.

From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.150712DOI Listing
February 2016

Making smart investment decisions in clinical research.

Trials 2015 Dec 29;16:590. Epub 2015 Dec 29.

School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-015-1123-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693420PMC
December 2015

Rituximab for Rheumatoid Arthritis.

Rheumatol Ther 2015 Dec 19;2(2):99-111. Epub 2015 Aug 19.

University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40744-015-0016-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883263PMC
December 2015

Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

Clin Rheumatol 2015 Aug 15;34(8):1427-33. Epub 2015 Jan 15.

Institute of Management & Innovation, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON, L5L 1C6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-014-2835-4DOI Listing
August 2015

Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a canadian multisite suspected rheumatoid arthritis inception cohort.

J Rheumatol 2015 Jan 15;42(1):46-54. Epub 2014 Nov 15.

From the Schulich School of Medicine and Dentistry, Department of Internal Medicine, University of Western Ontario, London, Ontario, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA; Rheumatology Division, Université de Sherbrooke, Sherbrooke, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph's Health Care, London, Ontario, Canada.G. Yang, MD, Schulich School of Medicine and Dentistry, Department of Internal Medicine, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, FRCPC, Rheumatology Division, Universite de Sherbrooke; C.A. Hitchon, MD, FRCPC, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, FRCPC; D. Tin, BSc Pharm, Southlake Regional Health Centre; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; E.C. Keystone, MD, FRCPC, Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, FRCPC, MPH, Schulich School of Medicine and Dentistry, Department of Internal Medicine, University of Western Ontario, and Rheumatology, St. Joseph's Health Care.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.131382DOI Listing
January 2015

Arthritis clinical trials at a crossroad.

J Rheumatol 2015 Jan;42(1):14-7

Canadian Rheumatology Research Consortium, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140717DOI Listing
January 2015

The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.

Ann Rheum Dis 2014 Dec 26;73(12):2144-51. Epub 2013 Aug 26.

Department of Rheumatology, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis & Autoimmune Diseases, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2013-203684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251190PMC
December 2014

Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis.

J Rheumatol 2014 Dec 1;41(12):2361-9. Epub 2014 Oct 1.

From the Department of Medicine, Division of Rheumatology, St. Joseph's Health Care London, University of Western Ontario, London; Rebecca McDonald Center for Arthritis and Autoimmune Disease, Mount Sinai Hospital, University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; Rheumatology Division, Université de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rheumatologie, Université de Montréal, Montreal, Quebec; Arthritis Center, University of Manitoba, Winnipeg, Manitoba, Canada; Inflammatory Arthritis Center, Hospital for Special Surgery, Department of Biostatistics, Harvard University, Boston, Massachusetts; Weill Cornell Medical College, Cornell University, New York, New York, USA.Dr. Barra has received honoraria from Hoffmann-La Roche Ltd., Amgen Canada Inc., AbbVie, and United Chemicals of Belgium (UCB). The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., UCB Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.).L. Barra, MD, MPH; J.E. Pope, MD, MPH, Department of Medicine, Division of Rheumatology, St. Joseph's Health Care London, University of Western Ontario; J.E. Orav, PhD, Department of Biostatistics, Harvard University; G. Boire, MD, MSc, Rheumatology Division, Université de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rheumatologie, Université de Montréal; C. Hitchon, MD, MSc, Arthritis Center, University of Manitoba; E.C. Keystone, MD, Rebecca McDonald Center for Arthritis and Autoimmune Disease, Mount Sinai Hospital, University of Toronto; J.C. Thorne, MD; D. Tin, BPharm, Southlake Regional Health Centre; V.P. Bykerk, MD, Rebecca McDonald Center for Arthritis and Autoimm

View Article

Download full-text PDF

Source
http://www.jrheum.org/content/41/12/2361.full.pdf
Web Search
http://www.jrheum.org/cgi/doi/10.3899/jrheum.140082
Publisher Site
http://dx.doi.org/10.3899/jrheum.140082DOI Listing
December 2014

Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.

J Rheumatol 2014 Nov 15;41(11):2104-13. Epub 2014 Aug 15.

From the University of Alberta, Edmonton, Alberta; Augurex Life Sciences Corp., North Vancouver, British Columbia; Mount Sinai Hospital, Toronto, Ontario, Canada; Quest Diagnostics Nichols Institute, San Juan Capistrano; Stanford University Medical Center, Palo Alto, California; Hospital for Special Surgery, New York, New York; Brigham and Women's Hospital, Boston, Massachusetts, USA; Vrije Universiteit University Medical Center; Academic Medical Center/University of Amsterdam; Jan van Breemen Research Institute, Reade organization, Amsterdam; the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; University of Cambridge, Cambridge; GlaxoSmithKline, Stevenage, UK.W.P. Maksymowych, MD, Professor of Medicine, University of Alberta; S.J. Naides, MD, Quest Diagnostics Nichols Institute; V. Bykerk, MD, Hospital for Special Surgery; K.A. Siminovitch, MD, Mount Sinai Hospital; D. van Schaardenburg, MD, Jan van Breemen Research Institute; M. Boers, MD, Vrije Universiteit University Medical Center; R. Landewé, MD, Academic Medical Center/University of Amsterdam; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center; P-P. Tak, MD, Academic Medical Center/University of Amsterdam, University of Cambridge, GlaxoSmithKline; M.C. Genovese, MD, Stanford University Medical Center; M.E. Weinblatt, MD, Brigham and Women's Hospital; E.C. Keystone, MD, Mount Sinai Hospital; O.S. Zhukov, MS; R.W. Abolhosn, BS; J.M. Popov, MD, PhD, Quest Diagnostics Nichols Institute; K. Britsemmer, MD, Jan van Breemen Research Institute; A.W. van Kuijk, MD, Academic Medical Center/University of Amsterdam; A. Marotta, PhD, Augurex Life Sciences Corp.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.131446DOI Listing
November 2014

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.

J Rheumatol 2014 Nov 15;41(11):2120-8. Epub 2014 Sep 15.

From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women's Hospital, Boston, Massachusetts, USA.M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E.C. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O'Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140238DOI Listing
November 2014

Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH).

J Rheumatol 2014 Nov 1;41(11):2161-6. Epub 2014 Oct 1.

From the Rheumatology Department, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Université de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Rheumatology Department, St. Joseph's Health Care, Western University, London; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Hospital for Special Surgery, Cornell University, New York, New York, USA.B. Kuriya, MD, MS, FRCPC; J. Xiong, MSc, PhD, Rheumatology Department, Mount Sinai Hospital, University of Toronto; G. Boire, MD, MSc, FRCPC, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, MSc, FRCPC, Arthritis Centre, University of Manitoba; J. Pope, MD, MPH, FRCPC, Rheumatology Department, St. Joseph's Health Care, Western University; J.C. Thorne, MD, FRCP, FACP; D. Tin, BSc PHm, RPh, CDE, CGP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Rheumatology Department, Mount Sinai Hospital, University of Toronto; V. Bykerk, MD, FRCPC, Rheumatology Department, Mount Sinai Hospital, University of Toronto, and Hospital for Special Surgery, Cornell University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140137DOI Listing
November 2014

Is structural damage evaluation by traditional radiographs still relevant in rheumatoid arthritis clinical trials?

J Rheumatol 2014 Nov;41(11):2325

Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140383DOI Listing
November 2014

Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?

Nat Rev Rheumatol 2014 Oct 5;10(10):578-9. Epub 2014 Aug 5.

Mount Sinai Hospital, 60 Murray Street, Room 2-006, Toronto, ON M5T 3L9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrrheum.2014.129DOI Listing
October 2014

Intravenous golimumab in rheumatoid arthritis.

Expert Rev Clin Immunol 2014 Jul 15;10(7):823-30. Epub 2014 May 15.

Mayo Clinic, 668 Humboldt St, Denver, CO 80218, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/1744666X.2014.918847DOI Listing
July 2014

Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.

Clin Exp Rheumatol 2013 Nov-Dec;31(6):919-25. Epub 2013 Nov 14.

Veterans Affairs Medical Center and University of Utah, Salt Lake City University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
March 2014

Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.

Rheumatology (Oxford) 2014 Mar 15;53(3):482-90. Epub 2013 Nov 15.

Department of Rheumatology, St Joseph's Health Care, 268 Grosvenor St., London, ON, N6A 4V2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/ket366DOI Listing
March 2014

Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.

J Rheumatol 2014 Feb 1;41(2):235-43. Epub 2013 Dec 1.

From the University of Toronto, Toronto, Ontario; the University of Montreal, Montreal, Quebec, Canada; AbbVie Inc., North Chicago, Illinois; and the University of California San Diego, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.121468DOI Listing
February 2014

Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.

J Rheumatol 2014 Feb 15;41(2):216-26. Epub 2014 Jan 15.

From Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, Ontario, Canada; US Medical Affairs-Immunology and Biometrics and Health Outcomes, Genentech, South San Francisco, California; University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.130489DOI Listing
February 2014

Factors associated with time to diagnosis in early rheumatoid arthritis.

Rheumatol Int 2014 Jan 30;34(1):85-92. Epub 2013 Aug 30.

Departments of Medicine and Community Health Sciences, University of Calgary, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-013-2846-5DOI Listing
January 2014

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.

J Rheumatol 2014 Jan 15;41(1):5-14. Epub 2013 Nov 15.

From the University of Toronto, Toronto, Ontario, Canada; Leiden University Medical Center, Leiden, The Netherlands; Academic Medical Center, Amsterdam, The Netherlands; AbbVie, Rungis, France; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co KG, Ludwigshafen, Germany; University of California San Diego, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.130543DOI Listing
January 2014

Achieving remission in clinical practice: lessons from clinical trial data.

Clin Exp Rheumatol 2013 Jul-Aug;31(4):621-32. Epub 2013 Apr 22.

Hospital for Special Surgery, New York City, USA.

View Article

Download full-text PDF

Source
October 2013

Cell-signaling therapy in rheumatoid arthritis.

Curr Rheumatol Rep 2013 Oct;15(10):368

The Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, 60 Murrray St., Room 2-006, Box 4, Toronto, Ontario, M5T 379, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-013-0368-5DOI Listing
October 2013

Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.

J Rheumatol 2013 Aug 1;40(8):1259-67. Epub 2013 Feb 1.

Department of Medicine, Division of Rheumatology, St. Joseph's Health Care London, University of Western Ontario, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.120736DOI Listing
August 2013

Identification of the NF-κB activating protein-like locus as a risk locus for rheumatoid arthritis.

Ann Rheum Dis 2013 Jul 6;72(7):1249-54. Epub 2012 Dec 6.

Mount Sinai Hospital Samuel Lunenfeld Research Institute and Toronto General Research Institute, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-202076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686260PMC
July 2013

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.

J Rheumatol 2013 Jul 15;40(7):1097-103. Epub 2013 May 15.

Immunology department, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.120584DOI Listing
July 2013

Therapies for active rheumatoid arthritis after methotrexate failure.

N Engl J Med 2013 Jul 11;369(4):307-18. Epub 2013 Jun 11.

Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE 68105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1303006DOI Listing
July 2013

Incidence and predictors of secondary fibromyalgia in an early arthritis cohort.

Ann Rheum Dis 2013 Jun 11;72(6):949-54. Epub 2012 Jul 11.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-201506DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488361PMC
June 2013

Rational therapy in RA: Issues in implementing a treat-to-target approach in RA.

Nat Rev Rheumatol 2013 Mar 12;9(3):137-8. Epub 2013 Feb 12.

University of Colorado Medical Center, Division of Rheumatology, 668 Humboldt St Denver, CO 80218, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrrheum.2013.18DOI Listing
March 2013

Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.

Arthritis Care Res (Hoboken) 2012 Dec;64(12):1794-803

UAB Center for Education and Research on Therapeutics, UAB Arthritis Clinical Intervention Program, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, FOT 805D, 510 20th Street South, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.21767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508159PMC
December 2012

Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis.

J Rheumatol 2012 Nov 1;39(11):2066-70. Epub 2012 Sep 1.

University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.120005DOI Listing
November 2012

Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study.

J Rheumatol 2012 Nov 1;39(11):2081-7. Epub 2012 Sep 1.

Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.120520DOI Listing
November 2012

Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.

Ann Rheum Dis 2012 Oct;71(10):1630-5

The Rebecca MacDonald Centre For Arthritis & Autoimmune Diseases, Mount Sinai Hospital, 60 Murray St, Box 4, Toronto, ON, Canada M5T 3L9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2011-143578DOI Listing
October 2012

Rheumatoid arthritis: where are we now?

Rheumatology (Oxford) 2012 Jul;51 Suppl 5:v1-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kes112DOI Listing
July 2012

Developing an effective treatment algorithm for rheumatoid arthritis.

Rheumatology (Oxford) 2012 Jul;51 Suppl 5:v48-54

University of Toronto, Department of Immunology, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kes122DOI Listing
July 2012

Future of RA: building on what we know and tailoring treatment.

Rheumatology (Oxford) 2012 Jul;51 Suppl 5:v55-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kes121DOI Listing
July 2012

Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.

J Rheumatol 2012 Jun 15;39(6):1155-8. Epub 2012 Apr 15.

Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.111341DOI Listing
June 2012